EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Atypical retrobulbar optic neuropathy after semaglutide escalation

Shivaprasad Channabasappa iD, Riddhi Das Gupta, Vidhya Chandran, Sai Prasad

JCEM Case Reports · 20.05.2026 · 4 (7)

DOI: 10.1210/jcemcr/luag108 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 29.05.2026. Verfasst von Shivaprasad Channabasappa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Sapthagiri Institute of Medical Sciences and Research Centre, Bengaluru 560090, India. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), is widely used to manage type 2 diabetes and obesity. Recent pharmacovigilance signals have reported an increased incidence of nonarteritic anterior ischemic optic neuropathy (NAION) among semaglutide users, although the absolute risk remains low. We report a man in his early 30s with class III obesity, obstructive sleep apnea, and prediabetes who developed acute, painless, asymmetric bilateral visual dysfunction four weeks after semaglutide escalation to 1 mg per week. Evaluation revealed retrobulbar optic neuropathy with asymmetric visual field defects, a central scotoma in the left eye, an altitudinal defect in the right eye, preserved optic disc appearance, and markedly delayed visual evoked potentials. Optical coherence tomography and neuroimaging were unremarkable. The presentation was atypical for NAION but did not fully align with classical demyelinating optic neuritis, yielding a mixed clinical picture. Semaglutide was discontinued immediately, and visual function remained stable over serial follow-up with adaptation to a persistent left central scotoma but no further deterioration. This case illustrates an atypical retrobulbar optic neuropathy in close temporal proximity to semaglutide dose escalation and underscores the need for clinical vigilance and strengthened pharmacovigilance as GLP-1RA use expands globally.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 receptor agonistNAIONobesityoptic neuropathyretrobulbar optic neuropathysemaglutide

Autor:innen und Institutionen

  • Department of Endocrinology, Sapthagiri Institute of Medical Sciences and Research Centre, Bengaluru 560090, India.
  • Department of Ophthalmology, Sankara Eye Hospital, Bengaluru 560037, India.
  • Department of Internal Medicine, S. Nijalingappa Medical College and HSK Hospital and Research Centre, Bagalkot 587102, India.

ORCID-Profile: Shivaprasad Channabasappa

Zitieren

APA

Channabasappa, S., Gupta, R. D., Chandran, V., & Prasad, S. (2026). Atypical retrobulbar optic neuropathy after semaglutide escalation. JCEM Case Reports, 4(7). https://doi.org/10.1210/jcemcr/luag108

Vancouver

Channabasappa S, Gupta RD, Chandran V, Prasad S. Atypical retrobulbar optic neuropathy after semaglutide escalation. JCEM Case Reports. 2026;4(7). doi:10.1210/jcemcr/luag108

BibTeX
@article{Channabasappa2026,
  author = {Channabasappa, Shivaprasad and Gupta, Riddhi Das and Chandran, Vidhya and Prasad, Sai},
  title = {Atypical retrobulbar optic neuropathy after semaglutide escalation},
  journal = {JCEM Case Reports},
  year = {2026},
  volume = {4},
  number = {7},
  doi = {10.1210/jcemcr/luag108}
}
Kostenlos starten →